Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Seizures 2Glioma 2Epilepsy 1Drug Resistant Epilepsy 1Brain Neoplasms 1

Interventions

Temozolomide 47Bevacizumab 41Radiotherapy 17Magnetic Resonance Spectroscopy 14Irinotecan 11Nivolumab 8Everolimus 7Radiation 6poly ICLC 5X-Rays 5Phantoms, Imaging 5Carboplatin 5pembrolizumab 4fluorodopa F 18 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Granulocyte-Macrophage Colony-Stimulating Factor 4Erlotinib Hydrochloride 4Carmustine 4ribociclib 3palbociclib 3ivosidenib 3antineoplaston A10 3Vorinostat 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Modafinil 3Lomustine 3Biopsy 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Glioma × perampanel × Clear all
NCT04497142 2024-08-05

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Dana-Farber Cancer Institute

Phase 1/2 Completed
12 enrolled 8 charts
CNS

Glioma, Seizures

NCT04650204 2023-06-22

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Mayo Clinic

Phase 4 Terminated
4 enrolled 9 charts
CNS

Drug Resistant Epilepsy, Epilepsy, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡